Move Over Roivant, Nuvation: EQRx Reveals Biggest Biopharma SPAC Merger This Year
Deal Gives Developer Of Low-Cost Drugs $1.8bn In New Cash
EQRx has raised at least $750m since it launched in January 2020 and will have $2bn to fund its ongoing development of low-cost drugs after merging with a special purpose acquisition corporation.
You may also be interested in...
Management tried to sidestep controversy around the approval of Aduhelm and said it remains confident the drug will be reimbursed.
Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.